Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome

Polycystic ovary syndrome (PCOS), affecting over 10% of women, is associated with insulin resistance, obesity, dyslipidaemia, fatty liver and adipose tissue dysfunction. Its pathogenesis is poorly understood and consequently treatment remains suboptimal. Prenatally androgenized (PA) sheep, a clinica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular and cellular endocrinology 2021-04, Vol.525, p.111196, Article 111196
Hauptverfasser: Siemienowicz, Katarzyna J., Furmanska, Klaudia, Filis, Panagiotis, Talia, Chiara, Thomas, Jennifer, Fowler, Paul A., Rae, Mick T., Duncan, W. Colin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 111196
container_title Molecular and cellular endocrinology
container_volume 525
creator Siemienowicz, Katarzyna J.
Furmanska, Klaudia
Filis, Panagiotis
Talia, Chiara
Thomas, Jennifer
Fowler, Paul A.
Rae, Mick T.
Duncan, W. Colin
description Polycystic ovary syndrome (PCOS), affecting over 10% of women, is associated with insulin resistance, obesity, dyslipidaemia, fatty liver and adipose tissue dysfunction. Its pathogenesis is poorly understood and consequently treatment remains suboptimal. Prenatally androgenized (PA) sheep, a clinically realistic model of PCOS, recapitulate the metabolic problems associated with PCOS. Fibroblast Growth Factor 21 (FGF21) is a metabolic hormone regulating lipid homeostasis, insulin sensitivity, energy balance and adipose tissue function. We therefore investigated the role of FGF21 in the metabolic phenotype of PA sheep. In adolescence PA sheep had decreased hepatic expression and circulating concentrations of FGF21. Adolescent PA sheep show decreased FGF21 signalling in subcutaneous adipose tissue, increased hepatic triglyceride content, trend towards reduced fatty acid oxidation capacity and increased hepatic expression of inflammatory markers. These data parallel studies on FGF21 deficiency, suggesting that FGF21 therapy during adolescence may represent a treatment strategy to mitigate metabolic problems associated with PCOS. •Prenatal androgenization of female sheep is a model of Polycystic Ovary Syndrome.•Fibroblast Growth Factor 21 is an important metabolic hormone.•Adolescent prenatally androgenized sheep have decreased Fibroblast Growth Factor 21.•Their metabolic profile parallel studies on Fibroblast Growth Factor 21 deficiency.•Targeting this hormone in adolescence may be a therapy in Polycystic Ovary Syndrome.
doi_str_mv 10.1016/j.mce.2021.111196
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2487746104</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030372072100040X</els_id><sourcerecordid>2487746104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-d7731e20eedeffeaa0d6cb0d938d63b2d1c27cf19f1b18e043730943474c872f3</originalsourceid><addsrcrecordid>eNp9kE9LwzAYh4Mobk4_gBfJ0Utn_nRNiycRN4WBHvQc0uSty2ibmmSDfnszph7NJZA8vx_v-yB0TcmcElrcbeedhjkjjM5pOlVxgqa0FCwryUKcoinhhGeCETFBFyFsCSFiwcpzNOF8sShywafo621Xg4-qxcvVklFsoLHaRmwD1tBHnz5sj-MGcAdR1a61Gg8qbtywGYN1rfscsWuw6rHb2z5RzkB7eBlcO-oxxMS7vfIjDmNvvOvgEp01qg1w9XPP0Mfy6f3xOVu_rl4eH9aZ5lURMyMEp8AIQBqpAaWIKXRNTMVLU_CaGaqZ0A2tGlrTEkjOBSdVznOR66Sg4TN0e-wdvPvaQYiys0FD26oe3C5IlpdC5AVNyRmiR1R7F4KHRg7edmloSYk8mJZbmUzLg2l5NJ0yNz_1u7oD85f4VZuA-yMAacm9BS-DttBrMNaDjtI4-0_9Nys1j3c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487746104</pqid></control><display><type>article</type><title>Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Siemienowicz, Katarzyna J. ; Furmanska, Klaudia ; Filis, Panagiotis ; Talia, Chiara ; Thomas, Jennifer ; Fowler, Paul A. ; Rae, Mick T. ; Duncan, W. Colin</creator><creatorcontrib>Siemienowicz, Katarzyna J. ; Furmanska, Klaudia ; Filis, Panagiotis ; Talia, Chiara ; Thomas, Jennifer ; Fowler, Paul A. ; Rae, Mick T. ; Duncan, W. Colin</creatorcontrib><description>Polycystic ovary syndrome (PCOS), affecting over 10% of women, is associated with insulin resistance, obesity, dyslipidaemia, fatty liver and adipose tissue dysfunction. Its pathogenesis is poorly understood and consequently treatment remains suboptimal. Prenatally androgenized (PA) sheep, a clinically realistic model of PCOS, recapitulate the metabolic problems associated with PCOS. Fibroblast Growth Factor 21 (FGF21) is a metabolic hormone regulating lipid homeostasis, insulin sensitivity, energy balance and adipose tissue function. We therefore investigated the role of FGF21 in the metabolic phenotype of PA sheep. In adolescence PA sheep had decreased hepatic expression and circulating concentrations of FGF21. Adolescent PA sheep show decreased FGF21 signalling in subcutaneous adipose tissue, increased hepatic triglyceride content, trend towards reduced fatty acid oxidation capacity and increased hepatic expression of inflammatory markers. These data parallel studies on FGF21 deficiency, suggesting that FGF21 therapy during adolescence may represent a treatment strategy to mitigate metabolic problems associated with PCOS. •Prenatal androgenization of female sheep is a model of Polycystic Ovary Syndrome.•Fibroblast Growth Factor 21 is an important metabolic hormone.•Adolescent prenatally androgenized sheep have decreased Fibroblast Growth Factor 21.•Their metabolic profile parallel studies on Fibroblast Growth Factor 21 deficiency.•Targeting this hormone in adolescence may be a therapy in Polycystic Ovary Syndrome.</description><identifier>ISSN: 0303-7207</identifier><identifier>ISSN: 1872-8057</identifier><identifier>EISSN: 1872-8057</identifier><identifier>DOI: 10.1016/j.mce.2021.111196</identifier><identifier>PMID: 33556473</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Androgens ; Androgens - metabolism ; Animals ; Biomarkers - metabolism ; Chemokines - metabolism ; Disease Models, Animal ; Female ; Fibroblast growth factor 21 (FGF21) ; Fibroblast Growth Factors - deficiency ; Fibroblast Growth Factors - metabolism ; Gene Expression Regulation ; Inflammation - pathology ; Lipids - chemistry ; Liver - metabolism ; Liver - pathology ; Metabolism ; Oxidation-Reduction ; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism ; Polycystic ovary syndrome ; Polycystic Ovary Syndrome - genetics ; Polycystic Ovary Syndrome - metabolism ; Polycystic Ovary Syndrome - physiopathology ; Prenatal programming ; Sex Characteristics ; Sexual Maturation ; Sheep ; Signal Transduction ; Subcutaneous Fat - metabolism ; Triglycerides - metabolism</subject><ispartof>Molecular and cellular endocrinology, 2021-04, Vol.525, p.111196, Article 111196</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-d7731e20eedeffeaa0d6cb0d938d63b2d1c27cf19f1b18e043730943474c872f3</citedby><cites>FETCH-LOGICAL-c396t-d7731e20eedeffeaa0d6cb0d938d63b2d1c27cf19f1b18e043730943474c872f3</cites><orcidid>0000-0002-4121-9354 ; 0000-0002-4522-9672 ; 0000-0003-3143-7902</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.mce.2021.111196$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33556473$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Siemienowicz, Katarzyna J.</creatorcontrib><creatorcontrib>Furmanska, Klaudia</creatorcontrib><creatorcontrib>Filis, Panagiotis</creatorcontrib><creatorcontrib>Talia, Chiara</creatorcontrib><creatorcontrib>Thomas, Jennifer</creatorcontrib><creatorcontrib>Fowler, Paul A.</creatorcontrib><creatorcontrib>Rae, Mick T.</creatorcontrib><creatorcontrib>Duncan, W. Colin</creatorcontrib><title>Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome</title><title>Molecular and cellular endocrinology</title><addtitle>Mol Cell Endocrinol</addtitle><description>Polycystic ovary syndrome (PCOS), affecting over 10% of women, is associated with insulin resistance, obesity, dyslipidaemia, fatty liver and adipose tissue dysfunction. Its pathogenesis is poorly understood and consequently treatment remains suboptimal. Prenatally androgenized (PA) sheep, a clinically realistic model of PCOS, recapitulate the metabolic problems associated with PCOS. Fibroblast Growth Factor 21 (FGF21) is a metabolic hormone regulating lipid homeostasis, insulin sensitivity, energy balance and adipose tissue function. We therefore investigated the role of FGF21 in the metabolic phenotype of PA sheep. In adolescence PA sheep had decreased hepatic expression and circulating concentrations of FGF21. Adolescent PA sheep show decreased FGF21 signalling in subcutaneous adipose tissue, increased hepatic triglyceride content, trend towards reduced fatty acid oxidation capacity and increased hepatic expression of inflammatory markers. These data parallel studies on FGF21 deficiency, suggesting that FGF21 therapy during adolescence may represent a treatment strategy to mitigate metabolic problems associated with PCOS. •Prenatal androgenization of female sheep is a model of Polycystic Ovary Syndrome.•Fibroblast Growth Factor 21 is an important metabolic hormone.•Adolescent prenatally androgenized sheep have decreased Fibroblast Growth Factor 21.•Their metabolic profile parallel studies on Fibroblast Growth Factor 21 deficiency.•Targeting this hormone in adolescence may be a therapy in Polycystic Ovary Syndrome.</description><subject>Androgens</subject><subject>Androgens - metabolism</subject><subject>Animals</subject><subject>Biomarkers - metabolism</subject><subject>Chemokines - metabolism</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Fibroblast growth factor 21 (FGF21)</subject><subject>Fibroblast Growth Factors - deficiency</subject><subject>Fibroblast Growth Factors - metabolism</subject><subject>Gene Expression Regulation</subject><subject>Inflammation - pathology</subject><subject>Lipids - chemistry</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Metabolism</subject><subject>Oxidation-Reduction</subject><subject>Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism</subject><subject>Polycystic ovary syndrome</subject><subject>Polycystic Ovary Syndrome - genetics</subject><subject>Polycystic Ovary Syndrome - metabolism</subject><subject>Polycystic Ovary Syndrome - physiopathology</subject><subject>Prenatal programming</subject><subject>Sex Characteristics</subject><subject>Sexual Maturation</subject><subject>Sheep</subject><subject>Signal Transduction</subject><subject>Subcutaneous Fat - metabolism</subject><subject>Triglycerides - metabolism</subject><issn>0303-7207</issn><issn>1872-8057</issn><issn>1872-8057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9LwzAYh4Mobk4_gBfJ0Utn_nRNiycRN4WBHvQc0uSty2ibmmSDfnszph7NJZA8vx_v-yB0TcmcElrcbeedhjkjjM5pOlVxgqa0FCwryUKcoinhhGeCETFBFyFsCSFiwcpzNOF8sShywafo621Xg4-qxcvVklFsoLHaRmwD1tBHnz5sj-MGcAdR1a61Gg8qbtywGYN1rfscsWuw6rHb2z5RzkB7eBlcO-oxxMS7vfIjDmNvvOvgEp01qg1w9XPP0Mfy6f3xOVu_rl4eH9aZ5lURMyMEp8AIQBqpAaWIKXRNTMVLU_CaGaqZ0A2tGlrTEkjOBSdVznOR66Sg4TN0e-wdvPvaQYiys0FD26oe3C5IlpdC5AVNyRmiR1R7F4KHRg7edmloSYk8mJZbmUzLg2l5NJ0yNz_1u7oD85f4VZuA-yMAacm9BS-DttBrMNaDjtI4-0_9Nys1j3c</recordid><startdate>20210405</startdate><enddate>20210405</enddate><creator>Siemienowicz, Katarzyna J.</creator><creator>Furmanska, Klaudia</creator><creator>Filis, Panagiotis</creator><creator>Talia, Chiara</creator><creator>Thomas, Jennifer</creator><creator>Fowler, Paul A.</creator><creator>Rae, Mick T.</creator><creator>Duncan, W. Colin</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4121-9354</orcidid><orcidid>https://orcid.org/0000-0002-4522-9672</orcidid><orcidid>https://orcid.org/0000-0003-3143-7902</orcidid></search><sort><creationdate>20210405</creationdate><title>Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome</title><author>Siemienowicz, Katarzyna J. ; Furmanska, Klaudia ; Filis, Panagiotis ; Talia, Chiara ; Thomas, Jennifer ; Fowler, Paul A. ; Rae, Mick T. ; Duncan, W. Colin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-d7731e20eedeffeaa0d6cb0d938d63b2d1c27cf19f1b18e043730943474c872f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Androgens</topic><topic>Androgens - metabolism</topic><topic>Animals</topic><topic>Biomarkers - metabolism</topic><topic>Chemokines - metabolism</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Fibroblast growth factor 21 (FGF21)</topic><topic>Fibroblast Growth Factors - deficiency</topic><topic>Fibroblast Growth Factors - metabolism</topic><topic>Gene Expression Regulation</topic><topic>Inflammation - pathology</topic><topic>Lipids - chemistry</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Metabolism</topic><topic>Oxidation-Reduction</topic><topic>Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism</topic><topic>Polycystic ovary syndrome</topic><topic>Polycystic Ovary Syndrome - genetics</topic><topic>Polycystic Ovary Syndrome - metabolism</topic><topic>Polycystic Ovary Syndrome - physiopathology</topic><topic>Prenatal programming</topic><topic>Sex Characteristics</topic><topic>Sexual Maturation</topic><topic>Sheep</topic><topic>Signal Transduction</topic><topic>Subcutaneous Fat - metabolism</topic><topic>Triglycerides - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Siemienowicz, Katarzyna J.</creatorcontrib><creatorcontrib>Furmanska, Klaudia</creatorcontrib><creatorcontrib>Filis, Panagiotis</creatorcontrib><creatorcontrib>Talia, Chiara</creatorcontrib><creatorcontrib>Thomas, Jennifer</creatorcontrib><creatorcontrib>Fowler, Paul A.</creatorcontrib><creatorcontrib>Rae, Mick T.</creatorcontrib><creatorcontrib>Duncan, W. Colin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular and cellular endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Siemienowicz, Katarzyna J.</au><au>Furmanska, Klaudia</au><au>Filis, Panagiotis</au><au>Talia, Chiara</au><au>Thomas, Jennifer</au><au>Fowler, Paul A.</au><au>Rae, Mick T.</au><au>Duncan, W. Colin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome</atitle><jtitle>Molecular and cellular endocrinology</jtitle><addtitle>Mol Cell Endocrinol</addtitle><date>2021-04-05</date><risdate>2021</risdate><volume>525</volume><spage>111196</spage><pages>111196-</pages><artnum>111196</artnum><issn>0303-7207</issn><issn>1872-8057</issn><eissn>1872-8057</eissn><abstract>Polycystic ovary syndrome (PCOS), affecting over 10% of women, is associated with insulin resistance, obesity, dyslipidaemia, fatty liver and adipose tissue dysfunction. Its pathogenesis is poorly understood and consequently treatment remains suboptimal. Prenatally androgenized (PA) sheep, a clinically realistic model of PCOS, recapitulate the metabolic problems associated with PCOS. Fibroblast Growth Factor 21 (FGF21) is a metabolic hormone regulating lipid homeostasis, insulin sensitivity, energy balance and adipose tissue function. We therefore investigated the role of FGF21 in the metabolic phenotype of PA sheep. In adolescence PA sheep had decreased hepatic expression and circulating concentrations of FGF21. Adolescent PA sheep show decreased FGF21 signalling in subcutaneous adipose tissue, increased hepatic triglyceride content, trend towards reduced fatty acid oxidation capacity and increased hepatic expression of inflammatory markers. These data parallel studies on FGF21 deficiency, suggesting that FGF21 therapy during adolescence may represent a treatment strategy to mitigate metabolic problems associated with PCOS. •Prenatal androgenization of female sheep is a model of Polycystic Ovary Syndrome.•Fibroblast Growth Factor 21 is an important metabolic hormone.•Adolescent prenatally androgenized sheep have decreased Fibroblast Growth Factor 21.•Their metabolic profile parallel studies on Fibroblast Growth Factor 21 deficiency.•Targeting this hormone in adolescence may be a therapy in Polycystic Ovary Syndrome.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>33556473</pmid><doi>10.1016/j.mce.2021.111196</doi><orcidid>https://orcid.org/0000-0002-4121-9354</orcidid><orcidid>https://orcid.org/0000-0002-4522-9672</orcidid><orcidid>https://orcid.org/0000-0003-3143-7902</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0303-7207
ispartof Molecular and cellular endocrinology, 2021-04, Vol.525, p.111196, Article 111196
issn 0303-7207
1872-8057
1872-8057
language eng
recordid cdi_proquest_miscellaneous_2487746104
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Androgens
Androgens - metabolism
Animals
Biomarkers - metabolism
Chemokines - metabolism
Disease Models, Animal
Female
Fibroblast growth factor 21 (FGF21)
Fibroblast Growth Factors - deficiency
Fibroblast Growth Factors - metabolism
Gene Expression Regulation
Inflammation - pathology
Lipids - chemistry
Liver - metabolism
Liver - pathology
Metabolism
Oxidation-Reduction
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism
Polycystic ovary syndrome
Polycystic Ovary Syndrome - genetics
Polycystic Ovary Syndrome - metabolism
Polycystic Ovary Syndrome - physiopathology
Prenatal programming
Sex Characteristics
Sexual Maturation
Sheep
Signal Transduction
Subcutaneous Fat - metabolism
Triglycerides - metabolism
title Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A45%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pubertal%20FGF21%20deficit%20is%20central%20in%20the%20metabolic%20pathophysiology%20of%20an%20ovine%20model%20of%20polycystic%20ovary%20syndrome&rft.jtitle=Molecular%20and%20cellular%20endocrinology&rft.au=Siemienowicz,%20Katarzyna%20J.&rft.date=2021-04-05&rft.volume=525&rft.spage=111196&rft.pages=111196-&rft.artnum=111196&rft.issn=0303-7207&rft.eissn=1872-8057&rft_id=info:doi/10.1016/j.mce.2021.111196&rft_dat=%3Cproquest_cross%3E2487746104%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2487746104&rft_id=info:pmid/33556473&rft_els_id=S030372072100040X&rfr_iscdi=true